DVV

You are so tough. Why don't you sign your name to you post big guy? I love these people that were here back in the day that can't seem to leave this place behind. Go start your trouble on your company board, if you haven't already, and leave ours alone. Why do you care so much? Don't you have something more important in your life?

 

An established pattern of abuse of power and greed is not complicated to understand. Are you telling me this guy somehow found religion, and stopped pushing the envelope with compliance once others were hired? Wouldn't evidence of this so called sign off be apparent to inspectors/investigators? Or are we talking the pharmaceutical industry version of OJ? Lord knows he didn't do it - a jury found him not guilty too

 

Come on. You are better than that last post. Spending five minutes on this board plowing through you clowns is not a full days work. More than half the people on this board are comprised of former employees given KV's current headcount. Maybe someone will give you a break and post another "who's hot" list, or talk about who slept with how whilst at the last sales meeting. That's definitely value add. And if you are a current employee, get off the site, and go out and sell more product.

 

You can't type or spell or read, MOVE ON or do you have some kind of love for your past? Don't worry about us selling our products, mind your own.

 

You are correct, I am better. I am the best and you well you are just little old you.

 

No

 

The bankrupt entity KV Pharmaceutical Co. has proposed to pay $12.8 million to settle allegations that it misled investors and artificially inflated the value of its stock, a law firm involved in the case announced Wednesday.
The class-action lawsuit, filed in 2008 in federal court in St. Louis, was led by public employee pension plans of Boston and Norfolk County, Mass. The settlement will not affect the restructured company KV Pharmaceutical, which emerged from bankruptcy last year.

The suit alleges that former officers of the Bridgeton-based drugmaker made false and misleading statements between June 2004 and January 2009 regarding KV’s compliance with federal quality-control standards of the Food and Drug Administration. The false statements pumped up the value of KV stock, the suit alleges, and the stock price plummeted once the alleged fraud became apparent to the market.

KV suspended shipments of FDA-approved drugs in late 2008 and early 2009 because of manufacturing problems and laid off hundreds of workers. KV’s now-defunct Ethex Corp. subsidiary pleaded guilty in 2010 to two felony counts for not telling the FDA about its quality-control problems related to its manufacture of pain medication. Marc Hermelin, KV’s former CEO, pleaded guilty in 2011 to two criminal misdemeanor charges of violating drug labeling law.